CorrlensCorrlens
Correlate

Correlation Analysis

Incyte Genomics Inc vs JPMorgan Chase & Co.

INCY vs JPM

+0.409

Moderate positive

When one moves up, the other tends to follow.

INCY logo

Incyte Genomics Inc

INCY

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Market cap 18.9B · 2,844 employees

JPM logo

JPMorgan Chase & Co.

JPM

JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with more than $4.4 trillion in assets. It is organized into four major segments: consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates and is subject to regulation in multiple countries.

Market cap 792.5B

Apr 9, 2021 — Apr 7, 2026Daily1,254 data pointsStockStockFinancials

Time Series

Relative Performance

Green: INCYGray: JPM36 of 1,254 points (sampled)

Who Moves First

JPM leads INCY by 6 days

JPM tends to move before INCY.

After testing 13 timing shifts, the strongest relationship was +0.422 (they moved in the same direction).

Do They Crash Together?

Correlation by Market Regime

How these series behave when markets are rising, falling, or diverging. A correlation that holds in drawdowns is very different from one that only works in rallies.

Both Rising

-0.250

14 periods · Return correlation when both series rose

Both Falling

+0.212

8 periods · Return correlation when both series fell

Diverging

-0.749

13 periods · Return correlation when series moved apart

R-Squared

16.7%

Share of variance in one series explained by the other.

Trend Agreement

57.6%

How often both series moved in the same direction period-to-period.

Overlap Quality

1,254

Deep shared window — 1,254 usable pairs.

Significance

p < 0.001

95% CI: [0.362, 0.454]

Scatter

XY Regression

48.15060708090100106.798.3100150200250300333.4Incyte Genomics IncJPMorgan Chase & Co.Data pointsFit (r = 0.409)

Pipeline

Data quality details

Pipeline Summary

1,254 paired data points survived the daily window.

Raw input

1,254

1,254

Normalized

1,254

1,254

Prepared

1,254

1,254

Aligned

1,254

1,254

Invalid removed

0

A: 0 / B: 0

Duplicates removed

0

A: 0 / B: 0

Alignment drops

0

A: 0 / B: 0

Series A

INCY logo

Incyte Genomics Inc

INCY

Market cap 18.9B · 2,844 employees

Stock · 1,254 raw → 1,254 prepared

Series B

JPM logo

JPMorgan Chase & Co.

JPM

Market cap 792.5B

Stock · 1,254 raw → 1,254 prepared

Sign agreement

100.0%

How often both values share the same sign.

Zero crossings

1

Estimated crossover points between normalized spreads.

Slope

2.1217

Linear regression slope.

Intercept

36.7729

Linear regression intercept.

Related Extremes

Highest and Lowest Correlated

Saved 7 hours ago · ID: stock-incy-vs-stock-jpm-daily